PRNewsWire
19 Mar 2026, 14:00 UTC · 26w ago
Verdict
Headline takes no side. We score INO −1.00 across four claims — strongly bearish.
−1.00strongly bearish
More negative than 95% of ticker scores this week
What the story claims
4 claims · scored −1 bearish … +1 bullish
A class action lawsuit has been filed against Inovio Pharmaceuticals (INO) alleging violations of federal securities laws.
More negative than 95% of claims this week
The lawsuit claims Inovio's CELLECTRA device manufacturing was deficient, making the 2024 BLA submission for INO-3107 unlikely.
Continue reading
5 related stories
Scored by the NIS engine · methodology.
Top 2 movers · tap to explore
More negative than 91% of claims this week
Allegations suggest Inovio lacked sufficient information to justify FDA accelerated approval or priority review for INO-3107.
So whatLoss of accelerated approval status significantly extends the time to market and reduces the immediate commercial valuation of the drug.
More negative than 87% of claims this week
The complaint alleges that defendants conducted securities offerings and gained tens of millions of dollars while making misleading statements.
More negative than 79% of claims this week
Which stocks this story touches
More negative than 95% of ticker scores this week
The company is facing a class action lawsuit alleging materially false and misleading statements regarding its product pipeline and regulatory prospects.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
GlobeNewsWire
5h ago
−24.6%
Price agrees with the score
$1.25 vs $1.66 close before publication (Mar 18) · not market-adjusted
INO chart →
